Schering-Plough Licenses Late-Stage Candidate For Use In Coronary Bypass Surgery
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering intends to continue development of PeriCor’s novel drug “at an accelerated pace,” the company told “The Pink Sheet” DAILY.